Table 1.
5/14 schedule 150–210 mg/day OPZ |
2/7 schedule 210–330 mg/day OPZ |
|
---|---|---|
Number of patients enrolled | 19 | 46 |
Continuing treatment | 0 | 8 (17.4) |
Discontinued treatment | 19 (100) | 38 (82.6) |
Adverse event | 11 (57.9) | 12 (26.1) |
Disease progression | 5 (26.3) | 19 (41.3) |
Lost to follow-up | 0 | 1 (2.2) |
PI decision | 1 (5.3) | 2 (4.3) |
Patient request | 2 (10.5) | 4 (8.7) |
OPZ, oprozomib; PI, principal investigator.